Resource Center

Sep 1, 2011

Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants


Physiologically based pharmacokinetic (PBPK) modelling can assist in the development of drug therapies and regimens suitable for challenging patient populations such as very young children. This study describes a strategy employing PBPK models to investigate the intravenous use of the neuraminidase inhibitor oseltamivir in infants and neonates with influenza.

Contact Us About This Journal Article